A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
1717 K Street NW, Suite 900
Washington, DC 20006-5349
(877) 363-6376
HELPLINE
